Sanofi $SNY Position Lifted by Boston Partners

Boston Partners lifted its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 4.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,999,818 shares of the company’s stock after purchasing an additional 154,974 shares during the quarter. Boston Partners owned about 0.16% of Sanofi worth $164,837,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in SNY. Independent Advisor Alliance lifted its position in shares of Sanofi by 8.3% during the 3rd quarter. Independent Advisor Alliance now owns 8,199 shares of the company’s stock valued at $375,000 after acquiring an additional 627 shares during the period. Stelac Advisory Services LLC acquired a new stake in shares of Sanofi in the 3rd quarter worth approximately $2,326,000. Voya Investment Management LLC acquired a new stake in shares of Sanofi in the 3rd quarter worth approximately $434,000. Rothschild Investment LLC increased its stake in Sanofi by 7.8% in the 3rd quarter. Rothschild Investment LLC now owns 3,847 shares of the company’s stock valued at $159,000 after purchasing an additional 277 shares in the last quarter. Finally, Cibc World Market Inc. increased its stake in Sanofi by 0.8% in the 3rd quarter. Cibc World Market Inc. now owns 482,981 shares of the company’s stock valued at $19,913,000 after purchasing an additional 3,903 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Stock Down 2.2%

Shares of NASDAQ:SNY opened at $46.06 on Friday. The company has a current ratio of 1.12, a quick ratio of 0.27 and a debt-to-equity ratio of 0.20. The firm has a market cap of $111.67 billion, a price-to-earnings ratio of 22.80, a PEG ratio of 1.29 and a beta of 0.31. The stock’s 50-day moving average price is $43.00 and its two-hundred day moving average price is $44.39. Sanofi has a 12-month low of $39.07 and a 12-month high of $50.60.

Sanofi (NASDAQ:SNY – Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.56 by $0.48. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. The company had revenue of $17.25 billion during the quarter, compared to the consensus estimate of $14.30 billion. During the same quarter in the prior year, the company posted $2.91 EPS. The company’s quarterly revenue was up 16.2% compared to the same quarter last year. On average, research analysts forecast that Sanofi will post 5.07 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on SNY shares. DZ Bank reiterated a “buy” rating on shares of Sanofi in a research report on Friday, July 31st. Royal Bank Of Canada initiated coverage on Sanofi in a research report on Tuesday, September 8th. They issued a “sector perform” rating for the company. Berenberg Bank reaffirmed a “buy” rating on shares of Sanofi in a research note on Monday, October 5th. UBS Group reiterated a “neutral” rating on shares of Sanofi in a research report on Thursday, September 17th. Finally, Wolfe Research began coverage on shares of Sanofi in a research note on Friday, October 9th. They issued a “peer perform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $53.00.

Read Our Latest Stock Analysis on Sanofi

Key Sanofi News

These are some of the SNY news items that stood out recently:

  • Neutral Sentiment: Reports say Sanofi is weighing a possible acquisition of Insmed, a biotech company with a market value of about $26 billion. A deal could add to Sanofi’s pipeline, but no transaction terms or confirmation were reported, leaving the potential cost and strategic impact uncertain. Article: Sanofi weighs potential Insmed takeover
  • Negative Sentiment: A shortage of Sanofi’s Pompe disease drugs has continued for more than three months because of manufacturing issues at its Irish facility. Some patients have missed critical infusions, raising concerns about supply reliability and potential reputational or commercial effects. Article: Pompe drug shortage
  • Negative Sentiment: Investors bought 2,521 put options on SNY, about 35% above the average daily volume. This may indicate increased hedging or bearish positioning, though options activity alone does not establish market direction.

Sanofi Profile

(Free Report)

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.

Read More

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.